NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2023 and provided a business update.
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.
Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.
Durante los últimos años se vio una notable evolución en aparatos eléctricos relacionados con la cocina, ya que salieron a la venta artículos sumamente interesantes, con una funcionalidad única que le permite a cualquier integrante de una casa pode …
Las freidoras de aire, un invento que cuida las vidas de las personas Read More »
Sony Corporation and Astellas Pharma Inc. announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate platform in oncology based on Sony’s unique polymeric material, “KIRAVIA™ Backbone.”
AlzeCure Pharma AB announced that the company is participating at Penser Market on May 25 at 14:05 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.
AlzeCure Participates at Penser Market on May 25 Read More »
Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company’s U.S. commercialization strategy from a clinical and regulatory perspective.
Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team Read More »
Beactica Therapeutics AB, the Swedish precision oncology company, announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.
RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE.
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.
